Agilent Technologies has announced that Robert W. McMahon, the Senior Vice President and Chief Financial Officer, will resign effective July 31, 2025, for personal reasons. His departure is not related to any disagreements regarding the company's financial practices. Rodney Gonsalves, currently serving as Vice President, Corporate Controller, and Principal Accounting Officer, will take on the role of interim CFO until a permanent successor is appointed.
The company plans to release its financial results for the third quarter of fiscal year 2025 on August 27, 2025, after market close. Agilent has indicated that it expects these results to fall within the previously provided guidance range. The company generated revenue of $6.51 billion in fiscal year 2024 and employs about 18,000 people globally, highlighting its position as a leader in analytical and clinical laboratory technologies.
linkJul 15, 2025 08:43:34
Agilent Technologies Inc. announced its financial results for the second quarter of fiscal year 2025, reporting revenue of $1.67 billion, which shows a growth of 6.0% compared to the same period last year. The company’s GAAP net income was $215 million, equating to earnings per share (EPS) of $0.75, a decrease of 29% from the prior year. In contrast, non-GAAP net income was $373 million with an EPS of $1.31, reflecting a 7% increase year-over-year. The company highlighted that its Ignite Transformation initiative has been a significant factor in driving financial success during this quarter.
For the full fiscal year 2025, Agilent has updated its revenue outlook to between $6.73 billion and $6.81 billion, indicating a growth of 3.4% to 4.6%. The non-GAAP EPS guidance for the year is projected to be in the range of $5.54 to $5.61. For the upcoming third quarter, Agilent anticipates revenue between $1.645 billion and $1.675 billion, representing an increase of 4.2% to 6.1%. The expected non-GAAP EPS for Q3 is between $1.35 and $1.37 per share.
linkMay 28, 2025 16:06:14
Agilent Technologies Inc. has appointed Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown, founder and CEO of Downtown Advisory, to its Board of Directors, effective May 21, 2025. Both new members bring extensive experience in the pharmaceutical and healthcare sectors, which is expected to support Agilent's growth strategy. The company is entering a three-year Ignite Transformation initiative, and the addition of Soriot and Gawlik Brown aims to enhance the board's expertise in strategy and innovation.
Heidi Kunz has retired from the Board after over 20 years of service, having joined at the inception of Agilent. The company expressed gratitude for her contributions to its development and success. The board chair highlighted the importance of refreshing the board to benefit shareholders, indicating a commitment to maintaining a diverse and experienced leadership team.
linkMay 21, 2025 09:00:10
Agilent Technologies announced first-quarter revenue of $1.68 billion for fiscal year 2025, marking a 1.4% increase compared to the same period last year. The Life Sciences and Diagnostics Markets Group achieved a revenue increase of 4%, while the Agilent CrossLab Group saw a 1% rise. Non-GAAP net income for the quarter was $377 million, reflecting a slight increase in earnings per share to $1.31. The company maintained its revenue and EPS expectations for the fiscal year 2025, projecting full-year revenue between $6.68 billion and $6.76 billion.
Conversely, GAAP net income fell to $318 million, a 6% decrease from the previous year, leading to a decline in earnings per share to $1.11. The Applied Markets Group reported a revenue drop of 4%, indicating challenges in this sector. Although the company expects revenue growth in the second quarter, the overall decline in GAAP earnings raises concerns regarding profitability. Agilent's management highlighted ongoing transformation efforts aimed at improving operational efficiency despite these mixed financial results.
linkFeb 26, 2025 16:05:37
Agilent Technologies reported a total revenue of $2.47 billion for fiscal year 2024, a decline from $2.78 billion in the previous year. The gross margin percentage also decreased from 56.7% in FY23 to 54.5% in FY24, indicating challenges in maintaining profit margins. Research and development expenses saw a reduction, but selling, general, and administrative expenses remained relatively stable across the quarters, contributing to an overall decrease in income from operations from $673 million in FY23 to $484 million in FY24.
On a positive note, the Agilent CrossLab segment showed resilience with total revenue increasing to $2.75 billion in FY24, up from $2.66 billion in FY23, and maintaining a consistent gross margin percentage. The operating margin for this segment improved slightly, reflecting better operational efficiency. The Applied Markets segment, however, experienced a revenue decline from $1.40 billion in FY23 to $1.30 billion in FY24, alongside a decrease in operating margin, indicating potential areas for improvement.
linkDec 13, 2024 09:00:19
Agilent Technologies reported a fourth-quarter revenue of $1.70 billion, which reflects a slight increase of 0.8% compared to the same period last year. The company also saw a non-GAAP net income of $418 million, translating to earnings per share of $1.46, up 6% from the previous year. In contrast, GAAP net income was $351 million, or $1.22 per share, marking a decline of 25% from the fourth quarter of 2023. The Agilent CrossLab Group showed positive growth with a 5% increase in revenue year-over-year, while the Life Sciences and Applied Markets Group experienced a decline of 1% in revenue during the same period.
For the full fiscal year 2024, Agilent reported a total revenue of $6.51 billion, down 4.7% from the previous year. Although GAAP net income increased by 6% year-over-year to $1.289 billion, non-GAAP net income fell by 3%. The company expects revenue for fiscal year 2025 to be in the range of $6.790 billion to $6.870 billion, indicating a potential growth of up to 5.5%. However, the first-quarter revenue guidance suggests a slight decline or minimal growth, which may reflect ongoing market challenges.
linkNov 25, 2024 16:06:14
Agilent Technologies has announced a new organizational structure aimed at enhancing its market-focused strategy and improving collaboration among its business groups. This reorganization will support Agilent's goal of becoming more customer-centric and is expected to strengthen its performance across three main business groups: Life Sciences and Diagnostics Markets Group, Applied Markets Group, and Agilent CrossLab Group, which collectively represent 100% of the company’s revenue. The changes include new leadership appointments, with Simon May, Mike Zhang, and Angelica Riemann taking key roles in their respective groups, signaling a commitment to operational transformation and growth in targeted markets.
On the negative side, the transition to this new structure comes with the retirement of Phil Binns, who has been a prominent figure in the company, set to leave in April 2025. Additionally, while the new organizational setup aims to enhance customer connections and market execution, it also introduces potential risks as the company adapts to this change. Agilent's upcoming financial results will still reflect the old structure, with the first quarter of 2025 being the first to show the impact of the new organization. This delay may create uncertainty among investors regarding the immediate effects of the restructuring.
linkNov 25, 2024 09:10:09
The company has submitted its financial statements in compliance with regulatory requirements. This action reflects the company's commitment to transparency and accountability in its financial reporting.
The report was officially signed by the Vice President and Assistant General Counsel, P. Diana Chiu, indicating that the necessary internal approvals were obtained. This step is crucial for maintaining investor trust and ensuring adherence to legal obligations.
linkSep 09, 2024 16:13:59
Agilent Technologies announced its financial results for the third quarter of fiscal year 2024, reporting a revenue of $1.58 billion, which reflects a decline compared to the previous year. However, the company achieved a significant increase in net income, reaching $282 million or $0.97 per share, a remarkable 155% rise from the same quarter last year. The company also raised its full-year revenue outlook, indicating confidence in its future performance despite the current market challenges.
While certain segments of Agilent's business, such as Life Sciences and Diagnostics, experienced revenue declines, the Agilent CrossLab Group reported a slight growth, showcasing some resilience in the company's operations. The overall outlook for the fourth quarter suggests a potential revenue range that may not significantly differ from the previous year, reflecting ongoing market pressures. Despite these challenges, Agilent's leadership emphasized strategic initiatives aimed at enhancing growth and operational efficiency.
linkAug 21, 2024 16:06:43
Agilent Technologies reported Q2 revenue of $1.57 billion, a decline of 8.4%. GAAP net income was $308 million, up 3% from the previous year. Non-GAAP net income was $356 million, down 4%. Full-year revenue outlook revised to $6.42-6.5 billion, with EPS guidance at $5.15-5.25. Agilent plans to repurchase $0.75 billion of its common stock and authorized a new $2.0 billion share repurchase program. Market recovery slower than expected, but the company is taking cost-cutting measures and remains optimistic about future opportunities.
linkMay 29, 2024 16:06:45